PROOVSTATION
3.3.2020 17:21:11 CET | Business Wire | Press release
ProovStation and GCA, a major European actor in the transport and industrial logistics sector, signed today a partnership with the aim of creating commercial synergies and supporting the development of the solutions offered by ProovStation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200303005747/en/
The aim of this agreement is to install 30 stations in all the automotive logistic sites of the Groupe Charles André. The deployment will start in April with the installation of the first 2 stations at Corbas (Lyon) and Fleury Merogis (Paris) sites.
For Serge Agneray, Director General of GCA Automotive Logistics division, this new equipment is part of their desire to find innovative solutions with added value for their customers.
GCA's Automotive Logistic branch, in strong growth, is composed of 32 sites in Europe. GCA offers many services to manufacturers, rental companies and vehicle sellers (new and used): transport (with 3.2 million vehicles per year), storage, preparation, maintenance, remarketing, 3D photo, and soon the automated inspection through the solution of ProovStation.
Thanks to their advanced Artificial Intelligence system, ProovStation gantries will allow GCA to offer a fully automated vehicle inspection in 3 seconds. During the passage of the car under the gantry, scratches of the order of a millimeter can be detected, which increases the precision and reduces the cost linked to the inspection.
“We are glad to count GCA as one of our trusted partners and we are looking forward to start this great collaboration which constitutes an important stage in our development. Furthermore, supporting in its activity a key player in the sector such as GCA, is a great recognition for our solution. It brings us closer to our goal, which is: make ProovStation the international standard for the car inspection” says Cédric BERNARD, CEO of ProovStation.
Delphine André, CEO of GCA adds "We are delighted to establish this partnership with ProovStation, a Start Up that shifts the lines in a profession in profound change, and will allow us to benefit our customers from innovative solutions that are always more efficient"
Last January, the Start Up announced its first commercial agreement with BCA Group, the European leader in used vehicle remarketing, aiming to deploy 40 inspection gantries, across Europe, in 13 countries. With this new contract, ProovStation further confirms the strong legitimacy and value of its vehicle inspection solution for the automotive industry.
ABOUT PROOVSTATION
ProovStation is a Deeptech Start Up specialized in Computer Vision. Its ambition is to industrialize, automate and standardize the global automotive inspection process. It reduces the total cost of car inspection and increase the efficiency of the whole process to improve the client and collaborator experience. ProovStation is an automated drive-through bay which detects and analyses vehicle damages. The system generates a 360-degree photo scan of the vehicle in less than 3 seconds and increases the accuracy of damage recognition while reducing inspection costs and greatly improving trust during the transfer of liability. This approach allows to cover all the angles and to capture all damages with an accuracy of one millimeter. The gantry identifies, quantifies and localizes all damages present on the vehicle through its Artificial Intelligence. It delivers a time stamped, geo-located and secured report via the Block Chain. It also offers extra services from a user-friendly dashboard including repair estimate, inspection comparison log, used car pricing, integration and KPI tracking, insurance report and other fully customized options.
ABOUT GCA
Founded in 1932, and currently leaded by Delphine André, granddaughter of its founder, Groupe Charles André (GCA) has developed and diversified its historical activities as road transporter of dangerous good. GCA is now able to intervene on the entire Supply chain in fields like aeronautics, food, automotive, Construction and minerals, chemistry, defense, energy, environment, rail and urban logistics. In 2019, GCA achieved a turnover of 1.4 Billion euros. In 15 countries, GCA employs over 9,400 people. GCA cultivates the values of autonomy, respect for commitments, humility and teamwork. The company attaches great importance to safety, quality of its human resources and training.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200303005747/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom